Tirzepatide: Dual GIP/GLP-1 Receptor Agonism in Preclinical Models

Tirzepatide (LY3298176) is a synthetic 39-amino-acid peptide engineered as a dual agonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R), with a C20 fatty diacid moiety for albumin binding [1]. It is structurally derived from the native GIP backbone with modifications biasing receptor signaling toward cAMP accumulation without recruiting β-arrestin at GLP-1R.

In recombinant cell systems, Tirzepatide activates GIPR with potency similar to native GIP and GLP-1R with reduced — but pharmacologically meaningful — potency relative to native GLP-1 [1]. This biased agonism has been hypothesized to reduce GLP-1R desensitization and underlies the “twincretin” designation in the preclinical literature [2].

In diet-induced obese (DIO) mice, chronic Tirzepatide dosing produced dose-dependent reductions in food intake, body weight, and adipose mass exceeding effects observed with matched-dose Semaglutide controls [3]. Concurrent improvements in glucose tolerance during oral glucose challenges and decreased HbA1c-equivalent markers were observed across rodent diabetes models [3].

Mechanistic work in GIPR and GLP-1R knockout mice has dissected the contribution of each receptor. The body-weight effect is preserved in GLP-1R knockouts but blunted in GIPR knockouts, suggesting GIPR engagement contributes meaningfully to the anorectic phenotype [2]. In isolated pancreatic islets from rodent and primate donors, Tirzepatide potentiated glucose-dependent insulin secretion in a dual-receptor-dependent manner [4].

Adipose tissue research has examined Tirzepatide’s effects on lipolysis and adipocyte differentiation, with cell-culture studies in 3T3-L1 adipocytes showing altered lipid-droplet morphology and lipogenic gene expression [5].

Frontier Peptide Labs supplies a research-grade Tirzepatide vial with third-party HPLC purity reports for laboratory research use only.

References

1. Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Mol Metab. 2018;18:3-14. DOI: 10.1016/j.molmet.2018.09.009
2. Samms RJ, et al. How may GIP enhance the therapeutic efficacy of GLP-1? Trends Endocrinol Metab. 2020;31(6):410-421. DOI: 10.1016/j.tem.2020.02.006
3. Min T, Bain SC. The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes. Diabetes Ther. 2021;12(1):143-157. DOI: 10.1007/s13300-020-00981-0
4. El K, et al. The incretin co-agonist tirzepatide requires GIPR for hormone secretion. Nat Metab. 2023;5(6):945-954. DOI: 10.1038/s42255-023-00811-0
5. Killion EA, et al. Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models. Sci Transl Med. 2018;10(472):eaat3392. DOI: 10.1126/scitranslmed.aat3392